A RCT Study in Schizophrenia Relapse Prevention

Not Applicable

• Conditions: Relapse Schizophrenia
• Interventions: Device: ITAREPS

• Registration Number: NCT01885923
• Lead Sponsor: Prague Psychiatric Center

Brief Summary

THE AIM OF THE PROJECT The main aim lies in the prevention of frequent relapses typical for schizophrenia and schizoaffective disorder by means of simple, highly cost-effective information technology-aided approach RESEARCH HYPOTHESIS A the end of 18 months study duration, patients in the active group enrolled in ITAREPS will demonstrate statistically significantly reduced risk of hospitalization, decreased number of hospitalization days and reduced direct inpatient costs in comparison to control group not using the program.

Detailed Description

The ITAREPS 2.0 program employs telecommunication and information technologies in order to detect fluctuations in longitudinal mental health status of patient with schizophrenia and thus signalize the very early stages of prodromes preceding relapse. This approach opens an avenue towards early pharmacological intervention. Subjects (150 patients with diagnosis of schizophrenia and schizoaffective disorder and their family members) will be randomized at a 1:1 ratio into the active or control group. Participants from the active group will be completing two separate versions of the 10-item Early Warning Signs Questionnaire (EWSQ) upon a weekly SMS request generated automatically by the system during 18 months study duration. In this group, automatically generated e-mail alert message feedback to the investigator will be activated in case of prodrome detection, prompting investigator to antipsychotic dose increase by 20%. The control (treatment-as-usual) group will not use ITAREPS system.

Study Timeline

• Study Start: 2012-08
• Study First Submitted: 2012-08-14
• Study First Submitted QC: 2013-06-24
• Study First Posted: 2013-06-25
• Status Verified: 2013-07
• Last Update Submitted: 2013-07-10
• Last Update Posted: 2013-07-12
• Primary Completion: 2014-07
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

For entry into the study, the following criteria MUST be met:

• Men and women, ages 18 to 60 years, inclusive.
• A diagnosis of schizophrenia or schizoaffective disorder according to ICD-10 classification.
• Having at least TWO psychiatric hospitalization for psychosis before the study enrollment.
• Severity (CGI-S) ≤ 3 at study Visit 1.
• All patients must be on stable doses of antipsychotic medication during the study entry.

Exclusion Criteria

• Organic mental disorder,
• mental disorder due to psychoactive substance use or mental retardation.
• Participation in another relapse prevention program.
• Hayward compliance rating scale score < 2 at Visit 1.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
20% antisychotic dose increase in prodromes	ITAREPS	Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.

Primary Outcome Measures

Name	Time	Method
Primary Objective: The hospitalization-free survival rate at 18 months in active group compared to the control group.	18 months

Secondary Outcome Measures

Name	Time	Method
Number of psychiatric hospitalization days	18months
Direct impatient costs	18months
Direct cost of outpatient antipsychotic medication	18months
Cumulative exposition to antipsychotic medication in both active ITAREPS and control groups	18months

Trial Locations

Locations (1)

Prague Psychiatric Center; 🇨🇿 Prague, Czech Republic